Elan rated as a buy for investors

Merrill Lynch is rating Elan as a buy for investors. The Irish-based pharmaceutical company has fallen out of favour with the market recently. It is expected to launch three new drugs next year, while new accounting practices are expected to raise the quality of the group's earnings next year. Merrill Lynch is forecasting the stock will trade up to $45 (€44).